LONG LIFE HOLDING Valuation

Is 4355 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4355 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 4355's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 4355's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4355?

Key metric: As 4355 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 4355. This is calculated by dividing 4355's market cap by their current revenue.
What is 4355's PS Ratio?
PS Ratio	0.2x
Sales	JP¥12.61b
Market Cap	JP¥1.91b

4355 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.6x
Enterprise Value/EBITDA	9.1x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 4355's PS Ratio compare to its peers?

The above table shows the PS ratio for 4355 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.8x
9214 Recovery InternationalLtd	1.1x	n/a	JP¥1.9b
189A D & M Company	1.6x	n/a	JP¥1.9b
7090 Ligua	0.5x	n/a	JP¥1.6b
2435 CEDAR.Co.Ltd	0.1x	n/a	JP¥2.6b
4355 LONG LIFE HOLDING	0.2x	n/a	JP¥1.9b

Price-To-Sales vs Peers: 4355 is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (0.8x).

Price to Sales Ratio vs Industry

How does 4355's PS Ratio compare vs other companies in the JP Healthcare Industry?

5 Companies	Price / Sales	Estimated Growth	Market Cap
3151 Vital KSK Holdings	0.1x	n/a	US$371.53m
3055 Hokuyaku Takeyama HoldingsInc	0.06x	n/a	US$114.82m
3154 Medius Holdings	0.06x	n/a	US$111.58m
3417 Ohki Healthcare HoldingsLtd	0.03x	n/a	US$74.09m

5 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 4355 is good value based on its Price-To-Sales Ratio (0.2x) compared to the JP Healthcare industry average (0.5x).

Price to Sales Ratio vs Fair Ratio

What is 4355's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4355 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.2x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 4355's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

FINDEX

JP¥20.5b

Offers medical systems, office systems, and Healthtech products in Japan.

3649

JP¥800.00

-0.7%

-12.5%

Charm Care

JP¥40.4b

Engages in nursing care business.

6062

JP¥1,238.00

2.1%

4.5%

Suzuken

JP¥383.2b

Primarily engages in the distribution of pharmaceuticals in Japan and internationally.

9987

JP¥4,936.00

-2.8%

-1.8%